Published in
American Association for the Advancement of Science, Science Translational Medicine, 504(11), 2019
DOI: 10.1126/scitranslmed.aax7392
Links
Tools
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Journal article published in 2019 by
Bradon R. McDonald 
,
Tania Contente-Cuomo,
Stephen-John Sammut ,
Ahuva Odenheimer-Bergman,
Brenda Ernst ,
Nieves Perdigones ,
Suet-Feung Chin ,
Maria Farooq ,
Rosa Mejia,
Patricia A. Cronin,
Karen S. Anderson,
Heidi E. Kosiorek,
Donald W. Northfelt,
Ann E. McCullough ,
Bhavika K. Patel
and other authors.
,
Tania Contente-Cuomo,
Stephen-John Sammut ,
Ahuva Odenheimer-Bergman,
Brenda Ernst ,
Nieves Perdigones ,
Suet-Feung Chin ,
Maria Farooq ,
Rosa Mejia,
Patricia A. Cronin,
Karen S. Anderson,
Heidi E. Kosiorek,
Donald W. Northfelt,
Ann E. McCullough ,
Bhavika K. Patel
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
A robust personalized ctDNA test, TARDIS, achieves high accuracy for residual disease after completion of neoadjuvant therapy.